# A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03760666** · PHASE1,PHASE2 · TERMINATED · sponsor: **Clear Creek Bio, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Brequinar/Brequinar + Ribavirin

## Key facts

- **NCT ID:** NCT03760666
- **Lead sponsor:** Clear Creek Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-20
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-02-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** No efficacy observed, COVID-19 caused sites to shut down
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760666, "A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03760666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*